Physician
ST Claire Medical Center INC
ST Claire Medical Center INC was paid $71.27M by Medicaid between Jan 2018 and Dec 2024, across 475 billing codes. Its largest line is 99284, emergency room visit (serious) — 9.7% of everything it billed.
33Billing provider infoST CLAIRE MEDICAL CENTER INC
MOREHEAD, KY 40351
MOREHEAD, KY 40351
33aNPI1124078696assigned 05/12/2006
33bProvider typePhysical Medicine & Rehabilitation Physician
28Total paid$71.27M
24GClaims1,862,443
24DCodes billed475
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physical Medicine & Rehabilitation Physician providers in Kentucky
Rank by total paid#1 of 29
Median peer was paid$31K
This provider vs. median2,279×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LLOYD, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 274,687 | $9.65M | |
| 2019 | 293,243 | $10.01M | |
| 2020 | 220,834 | $8.50M | |
| 2021 | 264,124 | $10.09M | |
| 2022 | 266,231 | $10.68M | |
| 2023 | 295,934 | $11.27M | |
| 2024incomplete | 247,390 | $11.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.7% | 40,907 | 33,263 | $6.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 33,091 | 28,493 | $4.10M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.8% | 18,394 | 9,179 | $2.73M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.2% | 6,948 | 6,244 | $2.29M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 9,576 | 6,523 | $2.07M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 9,109 | 6,814 | $1.99M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.6% | 68,580 | 56,051 | $1.86M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.6% | 66,220 | 57,228 | $1.85M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 33,782 | 21,546 | $1.74M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.8% | 45,244 | 39,780 | $1.31M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 46,203 | 39,582 | $1.27M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 14,377 | 8,739 | $1.25M |
463 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 7,815 | $1.19M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 5,396 | $1.19M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 26,607 | $1.15M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 15,324 | $1.08M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 14,144 | $1.03M |
| 93458 | 1.4% | 1,164 | $979K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 89,696 | $914K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 16,956 | $902K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 2,475 | $893K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 5,686 | $890K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 3,215 | $812K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 11,948 | $776K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 11,935 | $735K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,235 | $699K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,506 | $681K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,771 | $665K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 8,069 | $664K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 93,264 | $663K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,759 | $616K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,248 | $589K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,474 | $526K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,398 | $516K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,896 | $492K |
| 36415 | Collection of venous blood by venipuncture | <1% | 140,646 | $488K |
| 20610 | <1% | 6,988 | $464K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,639 | $450K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,367 | $442K |
| 93017 | <1% | 2,578 | $436K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28,963 | $425K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,197 | $421K |
| 73630 | <1% | 5,007 | $416K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,190 | $372K |
| S9129 | Occupational therapy, in the home, per diem | <1% | 10,493 | $372K |
| 99219 | <1% | 2,159 | $357K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,268 | $355K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,314 | $353K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,146 | $345K |
| 95811 | <1% | 619 | $342K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,603 | $322K |
| 73610 | <1% | 3,397 | $314K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,594 | $295K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,195 | $283K |
| 80061 | Lipid panel | <1% | 24,350 | $281K |
| 76770 | <1% | 2,064 | $281K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,356 | $267K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,120 | $256K |
| 94060 | <1% | 2,920 | $245K | |
| 73030 | <1% | 2,952 | $238K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,399 | $233K |
| 73130 | <1% | 2,791 | $233K | |
| 73110 | <1% | 2,915 | $226K | |
| 71250 | <1% | 1,318 | $216K | |
| 71271 | <1% | 1,098 | $210K | |
| 73562 | <1% | 2,104 | $204K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,461 | $200K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,779 | $190K |
| 87507 | <1% | 635 | $184K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,716 | $184K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,996 | $182K |
| 80074 | <1% | 4,449 | $182K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 192 | $181K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 22,378 | $178K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 629 | $178K |
| 76830 | Ultrasound, transvaginal | <1% | 1,808 | $177K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 379 | $176K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,429 | $175K |
| 94726 | <1% | 1,726 | $174K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,080 | $172K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,638 | $170K |
| 59025 | Fetal non-stress test | <1% | 1,250 | $164K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,004 | $162K |
| 84484 | <1% | 16,065 | $158K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 21,466 | $158K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,285 | $158K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 634 | $156K |
| 72110 | <1% | 1,722 | $153K | |
| 93971 | <1% | 1,724 | $153K | |
| 73564 | <1% | 1,537 | $151K | |
| 82607 | <1% | 11,816 | $149K | |
| 81025 | <1% | 20,114 | $148K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,875 | $146K |
| 82805 | <1% | 2,426 | $144K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,398 | $141K |
| 87522 | Neg quan hep c or qual rna | <1% | 3,959 | $141K |
| 76536 | <1% | 1,065 | $137K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 46,789 | $136K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 948 | $136K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,850 | $131K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 14,241 | $120K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 500 | $118K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,966 | $115K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 423 | $114K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,027 | $111K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,093 | $109K |
| 87902 | <1% | 477 | $109K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 4,953 | $108K |
| 96376 | <1% | 3,555 | $107K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,699 | $107K |
| 47562 | <1% | 157 | $103K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,081 | $101K |
| 73221 | <1% | 391 | $101K | |
| 87631 | <1% | 701 | $97K | |
| 83690 | <1% | 15,937 | $97K | |
| 73090 | <1% | 1,144 | $96K | |
| J3490 | Unclassified drugs | <1% | 2,167 | $95K |
| 85027 | <1% | 14,684 | $92K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 715 | $92K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,316 | $91K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,316 | $86K |
| 81001 | <1% | 26,263 | $82K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 125 | $80K |
| 88304 | <1% | 1,581 | $78K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,247 | $78K |
| 74018 | <1% | 2,695 | $76K | |
| 73080 | <1% | 786 | $74K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,777 | $74K |
| 72131 | <1% | 464 | $72K | |
| 73590 | <1% | 942 | $72K | |
| 94762 | <1% | 1,334 | $71K | |
| 95806 | <1% | 761 | $71K | |
| G0378 | Hospital observation service, per hour | <1% | 507 | $70K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 117 | $70K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,105 | $67K |
| 87077 | <1% | 10,851 | $65K | |
| 90837 | Psychotherapy session, about an hour | <1% | 2,389 | $65K |
| J8501 | Aprepitant, oral, 5 mg | <1% | 960 | $64K |
| 83880 | <1% | 2,218 | $62K | |
| 90715 | <1% | 3,651 | $61K | |
| 12001 | <1% | 559 | $61K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,229 | $61K |
| 87806 | <1% | 1,963 | $60K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,298 | $60K |
| 84702 | <1% | 4,309 | $60K | |
| 97161 | <1% | 2,333 | $60K | |
| 95886 | <1% | 759 | $59K | |
| 70486 | <1% | 282 | $58K | |
| 94729 | <1% | 1,885 | $58K | |
| 93975 | <1% | 373 | $58K | |
| 93880 | <1% | 284 | $58K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,469 | $57K |
| 87186 | <1% | 7,455 | $56K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,968 | $55K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 208 | $54K |
| 73140 | <1% | 734 | $53K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 527 | $52K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 10,370 | $52K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 408 | $51K |
| 36600 | <1% | 1,215 | $51K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,846 | $49K |
| 82728 | <1% | 4,316 | $49K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,396 | $47K |
| 83605 | <1% | 5,249 | $47K | |
| 29515 | <1% | 722 | $46K | |
| 87040 | <1% | 5,434 | $45K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 1,364 | $45K |
| 86850 | <1% | 5,287 | $45K | |
| 84439 | <1% | 5,488 | $45K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 288 | $44K |
| 82746 | <1% | 3,508 | $43K | |
| 51798 | <1% | 1,649 | $43K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,225 | $42K |
| 72141 | <1% | 135 | $41K | |
| 87430 | <1% | 2,700 | $38K | |
| 73502 | <1% | 1,619 | $38K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,678 | $37K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,783 | $37K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 61 | $37K |
| 74022 | <1% | 392 | $36K | |
| 83550 | <1% | 4,851 | $36K | |
| 83735 | <1% | 6,598 | $35K | |
| 85610 | <1% | 10,472 | $35K | |
| 76870 | <1% | 253 | $35K | |
| 82962 | <1% | 11,276 | $34K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 82 | $33K |
| 87493 | <1% | 1,179 | $32K | |
| 81000 | <1% | 10,206 | $32K | |
| 83540 | <1% | 5,588 | $31K | |
| 97162 | <1% | 1,116 | $31K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 239 | $31K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,805 | $31K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,070 | $29K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 135 | $28K |
| 81003 | <1% | 10,423 | $27K | |
| 97166 | <1% | 556 | $27K | |
| 81002 | <1% | 10,309 | $27K | |
| 29125 | <1% | 442 | $25K | |
| 88142 | <1% | 1,203 | $24K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 2,775 | $24K |
| 83970 | <1% | 782 | $24K | |
| 77066 | Tomosynthesis, mammo | <1% | 224 | $23K |
| 82043 | <1% | 5,061 | $23K | |
| 85007 | <1% | 6,192 | $21K | |
| 76000 | <1% | 387 | $20K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 782 | $20K |
| 84403 | <1% | 905 | $20K | |
| 87070 | <1% | 2,456 | $20K | |
| 85730 | <1% | 4,297 | $19K | |
| 85379 | <1% | 2,233 | $19K | |
| 86803 | <1% | 1,475 | $19K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,475 | $19K |
| 72050 | <1% | 191 | $19K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,898 | $19K |
| 93970 | <1% | 100 | $18K | |
| 74246 | <1% | 221 | $18K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 500 | $18K |
| 86140 | <1% | 3,758 | $17K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 326 | $17K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,000 | $17K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,973 | $17K |
| 84481 | <1% | 1,086 | $16K | |
| 76642 | <1% | 286 | $15K | |
| 87046 | <1% | 1,469 | $15K | |
| 86038 | <1% | 1,531 | $15K | |
| 92523 | <1% | 112 | $14K | |
| 83883 | <1% | 1,193 | $14K | |
| 86780 | <1% | 1,317 | $14K | |
| 87340 | <1% | 1,429 | $14K | |
| 72100 | <1% | 203 | $14K | |
| 45384 | <1% | 91 | $14K | |
| 86900 | <1% | 4,765 | $14K | |
| C1769 | Guide wire | <1% | 268 | $14K |
| 74019 | <1% | 171 | $14K | |
| 84146 | <1% | 757 | $14K | |
| 73560 | <1% | 200 | $13K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 624 | $13K |
| 86901 | <1% | 4,687 | $12K | |
| 27096 | <1% | 25 | $12K | |
| 76801 | <1% | 83 | $12K | |
| 90474 | <1% | 3,762 | $12K | |
| 85651 | <1% | 3,328 | $12K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 548 | $12K |
| 95816 | <1% | 58 | $12K | |
| 87081 | <1% | 1,701 | $12K | |
| 83001 | <1% | 700 | $12K | |
| 74420 | <1% | 60 | $12K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,563 | $11K |
| 90686 | <1% | 5,490 | $11K | |
| 86003 | <1% | 223 | $11K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 468 | $11K |
| 96127 | <1% | 1,515 | $11K | |
| 84100 | <1% | 2,695 | $11K | |
| 83921 | <1% | 611 | $11K | |
| 76882 | <1% | 131 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,407 | $10K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 205 | $10K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 433 | $10K |
| 87210 | <1% | 2,021 | $10K | |
| 20553 | <1% | 254 | $10K | |
| 86762 | <1% | 797 | $10K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 761 | $9K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,144 | $9K |
| 82570 | <1% | 1,980 | $9K | |
| 86480 | <1% | 162 | $9K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 400 | $9K |
| 84145 | <1% | 441 | $9K | |
| 87045 | <1% | 1,002 | $9K | |
| 87807 | <1% | 614 | $9K | |
| 70491 | <1% | 38 | $8K | |
| 87209 | <1% | 481 | $8K | |
| 86703 | <1% | 725 | $8K | |
| 86592 | <1% | 1,997 | $8K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 90 | $8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 129 | $8K |
| 80069 | <1% | 839 | $8K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 524 | $8K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 707 | $8K |
| 88307 | <1% | 69 | $8K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,759 | $8K |
| 84550 | <1% | 1,865 | $8K | |
| 10061 | <1% | 67 | $7K | |
| 82977 | <1% | 1,069 | $7K | |
| 83002 | <1% | 454 | $7K | |
| 83516 | <1% | 604 | $7K | |
| 86317 | <1% | 524 | $7K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 232 | $7K |
| 11721 | <1% | 1,008 | $7K | |
| 96367 | <1% | 233 | $7K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 386 | $7K |
| 52000 | <1% | 50 | $7K | |
| 17110 | <1% | 156 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 29 | $6K |
| 88312 | <1% | 149 | $6K | |
| 86318 | <1% | 383 | $6K | |
| 84153 | <1% | 432 | $6K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 369 | $6K |
| 87427 | <1% | 499 | $6K | |
| 83525 | <1% | 591 | $6K | |
| 90670 | <1% | 4,675 | $6K | |
| 91322 | <1% | 149 | $6K | |
| 10060 | <1% | 111 | $5K | |
| 76942 | <1% | 227 | $5K | |
| 95910 | <1% | 56 | $5K | |
| 82550 | <1% | 864 | $5K | |
| 70498 | <1% | 28 | $5K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 239 | $5K |
| 84156 | <1% | 1,556 | $5K | |
| 94618 | <1% | 113 | $5K | |
| 86677 | <1% | 196 | $5K | |
| 20605 | <1% | 75 | $5K | |
| 11043 | <1% | 94 | $5K | |
| 12002 | <1% | 44 | $5K | |
| 82950 | <1% | 1,000 | $4K | |
| 94664 | <1% | 157 | $4K | |
| 84112 | <1% | 48 | $4K | |
| 87177 | <1% | 498 | $4K | |
| 86376 | <1% | 362 | $4K | |
| 51701 | <1% | 129 | $4K | |
| 93225 | <1% | 311 | $4K | |
| 99201 | <1% | 167 | $4K | |
| 87088 | <1% | 307 | $4K | |
| 84703 | <1% | 613 | $4K | |
| 90480 | <1% | 198 | $4K | |
| 91321 | <1% | 85 | $4K | |
| 82330 | <1% | 341 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 204 | $3K |
| 74247 | <1% | 30 | $3K | |
| 72114 | <1% | 45 | $3K | |
| 83013 | <1% | 47 | $3K | |
| 73060 | <1% | 43 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 174 | $3K |
| 86704 | <1% | 318 | $3K | |
| 99188 | <1% | 489 | $3K | |
| 90677 | <1% | 1,035 | $3K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 287 | $3K |
| 86430 | <1% | 560 | $3K | |
| 90632 | <1% | 238 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 258 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 191 | $3K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 181 | $3K |
| 93226 | <1% | 127 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 52 | $3K |
| 69209 | <1% | 113 | $3K | |
| 95911 | <1% | 15 | $2K | |
| 78226 | <1% | 14 | $2K | |
| 72072 | <1% | 13 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 52 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 57 | $2K |
| 70496 | <1% | 13 | $2K | |
| 72128 | <1% | 14 | $2K | |
| 97597 | <1% | 72 | $2K | |
| 73700 | <1% | 12 | $2K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 53 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 391 | $2K |
| 0001A | <1% | 105 | $2K | |
| 82010 | <1% | 291 | $2K | |
| 20552 | <1% | 75 | $2K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 268 | $2K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 72 | $2K |
| 92551 | <1% | 398 | $2K | |
| 11056 | <1% | 130 | $2K | |
| 94010 | <1% | 40 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,631 | $2K |
| 87428 | <1% | 69 | $2K | |
| 29105 | <1% | 63 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $2K |
| 98926 | <1% | 313 | $2K | |
| 93923 | <1% | 13 | $2K | |
| 80055 | <1% | 38 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 423 | $1K |
| 72170 | <1% | 32 | $1K | |
| 86308 | <1% | 296 | $1K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 74 | $1K |
| 90651 | <1% | 768 | $1K | |
| 90734 | <1% | 1,291 | $1K | |
| 97165 | <1% | 32 | $1K | |
| 82272 | <1% | 311 | $1K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 26 | $1K |
| 12011 | <1% | 12 | $1K | |
| 93924 | <1% | 13 | $1K | |
| 82784 | <1% | 190 | $1K | |
| 82627 | <1% | 55 | $1K | |
| 90633 | <1% | 3,492 | $1K | |
| 82785 | <1% | 84 | $1K | |
| 95885 | <1% | 13 | $1K | |
| 98927 | <1% | 192 | $1K | |
| 73070 | <1% | 14 | $1K | |
| 73100 | <1% | 16 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 535 | $949.30 |
| 90656 | <1% | 329 | $948.01 | |
| 86256 | <1% | 87 | $937.76 | |
| 89055 | <1% | 207 | $899.23 | |
| 77062 | <1% | 14 | $853.02 | |
| 73600 | <1% | 21 | $850.18 | |
| G0008 | Administration of influenza virus vaccine | <1% | 93 | $832.41 |
| 82248 | <1% | 180 | $806.59 | |
| 83615 | <1% | 147 | $780.02 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 25 | $769.57 |
| 11730 | <1% | 13 | $767.02 | |
| 90680 | <1% | 3,432 | $761.23 | |
| 83498 | <1% | 24 | $745.56 | |
| 86708 | <1% | 73 | $735.38 | |
| 82105 | <1% | 42 | $732.22 | |
| 90649 | <1% | 133 | $725.97 | |
| 0011A | <1% | 71 | $707.28 | |
| 86235 | <1% | 20 | $668.07 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 57 | $657.11 |
| 82951 | <1% | 55 | $631.88 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 67 | $610.64 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 27 | $598.15 |
| 86696 | <1% | 41 | $576.66 | |
| 87075 | <1% | 81 | $532.31 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 96 | $504.62 |
| 86665 | <1% | 28 | $494.60 | |
| V2632 | Posterior chamber intraocular lens | <1% | 19 | $480.24 |
| 86617 | <1% | 32 | $478.59 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 86 | $460.72 |
| 85045 | <1% | 108 | $442.17 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 39 | $434.15 |
| 90710 | <1% | 1,286 | $429.15 | |
| 86695 | <1% | 41 | $406.69 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 52 | $382.20 |
| 85018 | <1% | 144 | $375.99 | |
| 99173 | <1% | 257 | $375.62 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $357.27 |
| 51702 | <1% | 13 | $357.12 | |
| 87400 | <1% | 16 | $353.72 | |
| 86705 | <1% | 37 | $352.11 | |
| 90723 | <1% | 2,692 | $338.14 | |
| 80164 | <1% | 26 | $333.53 | |
| 77085 | <1% | 14 | $316.62 | |
| 86663 | <1% | 26 | $310.16 | |
| 87301 | <1% | 32 | $290.94 | |
| 80076 | <1% | 29 | $278.43 | |
| 84402 | <1% | 13 | $274.36 | |
| 83520 | <1% | 26 | $273.90 | |
| 96368 | <1% | 14 | $244.49 | |
| 93296 | <1% | 85 | $238.92 | |
| 87350 | <1% | 18 | $238.65 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 32 | $212.95 |
| 86664 | <1% | 14 | $208.40 | |
| 88300 | <1% | 12 | $202.47 | |
| 84460 | <1% | 47 | $191.80 | |
| 84450 | <1% | 47 | $190.02 | |
| 90700 | <1% | 1,131 | $184.02 | |
| 90648 | <1% | 2,637 | $176.37 | |
| 90716 | <1% | 1,090 | $169.71 | |
| 90707 | <1% | 1,033 | $168.73 | |
| 86431 | <1% | 31 | $163.52 | |
| 86039 | <1% | 15 | $157.79 | |
| 86580 | <1% | 31 | $146.53 | |
| 86800 | <1% | 13 | $140.33 | |
| 82365 | <1% | 14 | $135.67 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 14 | $132.12 |
| 82952 | <1% | 39 | $131.75 | |
| 0071A | <1% | 12 | $124.00 | |
| 98925 | <1% | 21 | $122.00 | |
| 82150 | <1% | 13 | $103.32 | |
| 99205 | Prolong outpt/office vis | <1% | 13 | $92.72 |
| 84520 | <1% | 33 | $85.32 | |
| 90696 | <1% | 821 | $78.87 | |
| 90662 | <1% | 36 | $73.04 | |
| 90697 | <1% | 1,187 | $71.61 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 14 | $68.81 |
| 90685 | <1% | 335 | $58.82 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 21 | $52.62 |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 28 | $35.83 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 17 | $35.33 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14 | $31.24 |
| 36416 | <1% | 14 | $29.18 | |
| 93280 | <1% | 16 | $18.08 | |
| 90647 | <1% | 413 | $4.63 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 98 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLLOYD, DONALD (CEO/ PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| ST Claire Medical Center INC. | Morehead, KY | $4.05M |
| ST. Claire Medical Center, INC | Morehead, KY | $3.32M |
| ST Claire Medical Center, INC., | Morehead, KY | $3.31M |
| ST Claire Medical Center, INC | Morehead, KY | $3.29M |
| ST. Claire Medical Center, INC | Morehead, KY | $3.11M |
| ST Claire Medical Center, INC., | Morehead, KY | $2.42M |
| ST. Claire Medical Center | Morehead, KY | $2.40M |
| ST. Claire Medical Center, INC. | Morehead, KY | $2.09M |
| ST Claire Regional Radiology Physicians Services | Morehead, KY | $1.83M |
| ST Claire Medical Center, INC., | Morehead, KY | $1.46M |
| ST. Claire Medical Center,inc | Olive Hill, KY | $1.13M |
| ST. Claire Medical Center, INC | Owingsville, KY | $964K |
| ST. Claire Medical Center,inc | Sandy Hook, KY | $948K |
| ST. Claire Medical Center, INC | Frenchburg, KY | $877K |
| ST Claire Medical Center, INC | Morehead, KY | $760K |
| ST. Claire Medical Center, INC | Morehead, KY | $672K |
| ST. Claire Medical Center, INC. | Morehead, KY | $411K |
| ST. Claire Medical Center INC. | Morehead, KY | $371K |
| ST Claire Medical Center INC. | Morehead, KY | $115K |
| ST. Claire Medical Center, INC. | Morehead, KY | $20K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.